<DOC>
	<DOCNO>NCT00285077</DOCNO>
	<brief_summary>The primary objective ass long term safety/tolerability 4 mg/day SR57667B comparison placebo patient mild-to-moderate Alzheimer 's Disease ( AD ) . A secondary objective describe long term progression Alzheimer 's symptom patient treat 4 mg/day SR57667B .</brief_summary>
	<brief_title>Long-Term Safety Extension With SR57667B Patients With Alzheimer 's Disease</brief_title>
	<detailed_description>Multinational , multicenter , randomize , parallel-group , double-blind , phase II study</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Patients participate Study EFC5286 complete study . Patient , identify caregiver , applicable , patient surrogate ( primary relative , legal guardian , medical proxy ) give informed write consent capable follow study procedure specifically LTS5283 extension . Females pregnant breastfeeding . Females child bear potential ( premenopausal female biologically capable become pregnant ) must confirm negative serum bHCG pregnancy test screen visit , must use acceptable method birth control .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Alzheimer disease</keyword>
	<keyword>nerve growth factor</keyword>
	<keyword>Clinical Trial</keyword>
</DOC>